The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...

The firm will use the funds to advance its KIR-CAR platform, which adapts dual receptors from NK cells to allow CAR T cells to rest when not actively targeting tumors.

The firms plan to integrate and standardize datasets and registries from patient-led groups and identify cohorts for use in clinical trials.

The firm is now expecting double the gross proceeds from its previously announced common stock and conversable senior note offerings.

The company is hoping to seek accelerated approval in first-line HLA-A*A2:01-negative metastatic uveal melanoma based on data ...

The funds will help the combined firm, which will operate as Obsidian and apply to trade on the Nasdaq, advance an investigational TIL therapy for melanoma and lung cancer.

PrecisionLife and Ovation.io on Wednesday said they inked an agreement to launch a consumer-facing genetic test for identifying patients' likelihood of responding to GLP-1 receptor agonists. The ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.

Researchers believe the therapy, which targets CD83, can selectively target leukemia cells and treat side effects of stem cell transplants.

The document outlines the non-clinical sequencing and bioinformatics data sponsors need to submit as part of INDs and BLAs for gene-editing therapies.

The firms submitted an application to the EMA seeking to begin a Phase IIb trial of vortosiran for stroke prevention in atrial fibrillation.

D Path will use its AI-enabled platform to analyze H&E-stained tumor biopsy slides and identify biomarkers of response to an undisclosed Daiichi ADC program.